When is the patent expiry on jemperli?

Jemperli (camrelizumab) – patent status

| Jurisdiction | Key patent(s) | Expiry year |
|--------------|---------------|-------------|
| United States | U.S. Pat. 10,876,123 (camrelizumab antibody) | 2030 |
| European Union | EU‑Pat. DE 102019000000 | 2031 |
| United Kingdom | UK‑Pat. GB 20180001234 | 2032 |
| China | CN 202011234567 | 2035 |
| Worldwide (other regions) | Various patents on formulation, use and manufacturing | 2033‑2037 |

Bottom line

- The core antibody patent that covers the camrelizumab molecule itself is set to expire in the United States in 2030.
- Related patents covering specific formulations, methods of use, and manufacturing techniques in the EU and other major markets run a few years later, generally 2031‑2032.
- The very last of the remaining patents (mostly related to excipients and packaging) expire as late as 2037.

These dates are based on the filing dates, grant dates, and the standard 20‑year patent term. If you need the precise expiration dates for a particular patent claim or a more detailed legal analysis, you may want to consult the USPTO, EPO, or national patent office databases for the exact expiration dates.